# Hypera Pharma posts R$453.9 million profit and record cash flow after working-capital overhaul

*Net revenue rises 16%, EBITDA margin back to pre-optimization levels; company redeems costlier debt and reinforces governance.*

- Published: 2025-10-28
- Section: Insights
- URL: https://brazilstockguide.com/insights/hypera-pharma-posts-r453-9-million-profit-and-record-cash-flow-after-working-capital-overhaul/

![Hypera Pharma](https://i0.wp.com/brazilstockguide.com/wp-content/uploads/2025/08/hypera_pharma.jpg?fit=1024%2C512&ssl=1)

*Hypera Pharma*

**By Brazil Stock Guide –** **Hypera Pharma (B3: HYPE3)** delivered a strong earnings recovery in the third quarter of 2025, reporting **net income of R$453.9 million**, up **22.6%** from a year earlier, and **net revenue of R$2.23 billion**, an increase of **16.3%**. The **EBITDA margin reached 34%**, returning to the level seen before the company’s working-capital optimization process. The performance reflects faster **pharmaceutical retail sell-out growth**, up **8.3%**, outpacing the market’s 6.4%, and the full benefit of the restructuring completed in the previous quarter, which cut receivable days from **126 to 58**.

The company posted **R$853.6 million in operating cash flow**, its highest ever for a single quarter, while reducing working-capital investments to **30% of annualized net revenue**, from **54%** a year earlier. The gains in efficiency lowered **net debt to R$7.27 billion**, or **2.4× annualized EBITDA**. Hypera also completed a **R$1 billion, five-year debenture issuance** at a record-low spread of **CDI + 0.75%**, used to redeem higher-cost notes and extend maturities.

“The combination of sell-out growth and record cash generation demonstrates the structural gains achieved after the capital-efficiency cycle,” the company said in its earnings release. Stronger sales in **flu, pain relief, gastroenterology, cardiology, and skincare** categories were fueled by recent product launches and higher **digital-media and point-of-sale investments**.

With margins back to pre-optimization levels, Hypera reaffirmed its focus on **sustainable growth and governance improvement**, updating board committees and approving **R$185.1 million in interest on equity** (R$0.29 per share). Supported by a resilient portfolio of leading OTC and prescription brands and a robust innovation pipeline, the company is well positioned to capture Brazil’s next phase of pharmaceutical expansion — balancing scale, discipline, and cash efficiency.

---

Source: Brazil Stock Guide, https://brazilstockguide.com/insights/hypera-pharma-posts-r453-9-million-profit-and-record-cash-flow-after-working-capital-overhaul/
